EUVIMEDEUVIMED entdecken
Fallbericht

Adalimumab as a cause of kidney injury in patients with Crohn’s disease

Krzysztof Skoczyński, Jan Koziej, Sylwia Szymańska, Łukasz Obrycki, Ryszard Grenda, Mieczysław Litwin iD

Pediatric Nephrology · 2024

DOI: 10.1007/s00467-024-06338-0 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Nephrology, 2024. Verfasst von Krzysztof Skoczyński und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Kidney Transplantation and Hypertension, The Children`s Memorial Health Institute, Warsaw, Poland. Hauptthemen laut MEDLINE: Acute Kidney Injury, Adalimumab, Crohn Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Adalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNFα) used to treat inflammatory bowel diseases. It can cause kidney injury (KI). CASE DIAGNOSIS/TREATMENT: We describe two pediatric patients with Crohn's disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function. CONCLUSIONS: Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryAdalimumabCrohn DiseaseAdolescentHumansMaleAnti-Inflammatory Agents

Stichwörter der Autor:innen

AdalimumabCrohn’s diseaseDrug reactionKidney injury

Substanzen

AdalimumabAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Nephrology, Kidney Transplantation and Hypertension, The Children`s Memorial Health Institute, Warsaw, Poland.
  • Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland.
  • Department of Pathology, The Children`s Memorial Health Institute, Warsaw, Poland.
  • Department of Nephrology, Kidney Transplantation and Hypertension, The Children`s Memorial Health Institute, Warsaw, Poland. m.litwin@ipczd.pl.
  • Chair of Pediatric Nephrology, The Center of Continuing Medical Education, Warsaw, Poland. m.litwin@ipczd.pl.

ORCID-Profile: Mieczysław Litwin

Zitieren

APA

Skoczyński, K., Koziej, J., Szymańska, S., Obrycki, Ł., Grenda, R., & Litwin, M. (2024). Adalimumab as a cause of kidney injury in patients with Crohn’s disease. Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06338-0

Vancouver

Skoczyński K, Koziej J, Szymańska S, Obrycki Ł, Grenda R, Litwin M. Adalimumab as a cause of kidney injury in patients with Crohn’s disease. Pediatric Nephrology. 2024. doi:10.1007/s00467-024-06338-0

BibTeX
@article{Skoczyski2024,
  author = {Skoczyński, Krzysztof and Koziej, Jan and Szymańska, Sylwia and Obrycki, Łukasz and Grenda, Ryszard and Litwin, Mieczysław},
  title = {Adalimumab as a cause of kidney injury in patients with Crohn’s disease},
  journal = {Pediatric Nephrology},
  year = {2024},
  doi = {10.1007/s00467-024-06338-0}
}
Kostenlos starten →